Skip to main content

Table 1 Clinical background of included studies

From: Surgical outcomes of hepatocellular carcinoma with biliary tumor thrombus: a systematic review

First author (Year)

No.

M/F

Age (years) a

BTT type Ma/Mi

HBsAg n (%)

Anti-HCV n (%)

Cirrhosis n (%)

TS (cm) a

MT n (%)

VI n (%)

PD n (%)

IM n (%)

TCA n (%)

Satoh (2000) [5]

17

15/2

58.2

17/0

5 (29.4)

11 (64.8)

5 (29.4)

Shiomi (2001) [6]

17

15/2

58.8

17/0

7 (46.7)

3 (17.6)

6 (35 %)

6.1

12/16 (75)

13 (76)

0 (0)

5 (29)

Peng (2004) [7]

15 b

10/5

49

15/0

13 (86.7)

5.1

2 (13.3)

5 (33.3)

Qin (2004) [8]

34

28/6

48.5

34/0

34 (100)

32 (94.1)

6.4

34 (100)

Yeh (2004) [9]

17

14/3

52.3

17/0

3.8

12/16 (75)

3/11 (27.2)

5/16 (83.3)

2/11 (18.2)

Esaki (2005) [12]

38

32/6

62

19/19

8 (21.1)

10 (26.3)

6.2

19 (50)

27 (71)

11 (28.9)

19 (50)

Ikenaga (2009) [13]

15

12/3

66

10/5

4 (27.7)

7 (46.7)

5.0

6 (40)

12/14 (85.7)

10 (66.7)

2 (13.3)

Luo (2009) [14]

48 c

48/0

6.2

Noda (2011) [15]

22

21/1

58

22/0

15 (68.1)

5 (22.7)

6 (27.2)

>5, n = 9

20 (90.9)

13 (59)

18 (81.8)

Shao (2011) [16]

27

24/3

47.1

24/3

26 (96.7)

0 (0)

18 (66.7)

>5, n = 10

17 (62.9)

26 (96.3)

5 (18.5)

21 (77.7)

Yu (2011) [17]

20d

17/3

50.6

20/0

16 (80)

14 (70)

4.5

12 (60)

13 (65)

4 (20)

15 (75)

Moon (2013) [18]

73

52/21

54.2

73/0

59 (80.8)

2 (2.8)

62 (84.9)

5.8

11 (15)

53 (72.6)

54 (74)

25 (34.2)

Meng (2014) [19]

35

24/11

51.3

28/7

26 (74.3)

0 (0)

25 (65.8)

>5, n = 24

15 (42.8)

10 (25.8)

10 (25.8)

24 (68.6)

Oba (2014) [20]

13

12/1

61

13/0

4 (30.7)

5 (38.5)

3 (23)

4.4

2 (15.4)

12 (92.3)

Kasai (2015) [21]

44

35/9

64

44/0

8 (18.2)

21 (52.5)

14 (31.8)

5.8

16 (36.4)

31 (70.4)

18 (40.9)

Kim (2015) [22]

31

21/10

53

0/31

26 (83.9)

1 (3.2)

4.8

28 (90.3)

1 (3.2)

8 (25.8)

7 (22.5)

Rammohan (2015) [23]

39

28/11

52.1

39/0

7 (17.9)

2 (5.1)

Excluded

5.6

Wong (2015) [24]

37

29/8

57

37/0

30 (81.1)

6

15 (29.7)

25 (67.6)

11 (29.7)

35 (94.6)

Yamamoto (2015) [25]

19

19/0

67

19/0

7 (36.8)

4 (21)

6 (31.5)

4.3

Zeng (2015) [26]

37

33/4

50

30/7

29 (78.4)

33 (89.2)

4.9

9 (24.3)

25 (67.5)

23 (62.2)

6 (16.2)

  1. M male, F female, Ma macroscopic, Mi microscopic, HBsAg hepatitis B surface antigen, anti-HCV hepatitis C virus antibody, ST solitary tumor, TS tumor size, MT multiple tumor, VI vascular invasion, PD poor differentiation, IM intrahepatic metastasis, TCA tumor capsule absence
  2. a mean or median
  3. b including 1 patients underwent liver transplantation; c including 5 patients underwent liver transplantation; d including 2 patients underwent liver transplantation